Nuvectis Pharma, Inc. (NVCT) Shareholder Equity
- 2026-06-30: Additional Paid in CapitalUSD $121.84M; Retained Earnings (Accumulated Deficit)USD $-112.76M; Stockholders' Equity Attributable to ParentUSD $9.08M; Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based CompensationUSD (m).
- 2026-03-31: Additional Paid in CapitalUSD $119.96M; Retained Earnings (Accumulated Deficit)USD $-105.74M; Stockholders' Equity Attributable to ParentUSD $14.22M; Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based CompensationUSD (m).
- 2025-12-31: Additional Paid in CapitalUSD $118.10M; Retained Earnings (Accumulated Deficit)USD $-99.69M; Stockholders' Equity Attributable to ParentUSD $18.41M; Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based CompensationUSD (m).
- 2025-09-30: Additional Paid in CapitalUSD $116.38M; Retained Earnings (Accumulated Deficit)USD $-92.37M; Stockholders' Equity Attributable to ParentUSD $24.01M; Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based CompensationUSD (m).
Nuvectis Pharma, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Additional Paid in Capital USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation USD |
|---|---|---|---|---|
| 2026-06-30 | $121.84M | $-112.76M | $9.08M | (m) |
| 2026-03-31 | $119.96M | $-105.74M | $14.22M | (m) |
| 2025-12-31 | $118.10M | $-99.69M | $18.41M | (m) |
| 2025-09-30 | $116.38M | $-92.37M | $24.01M | (m) |
| 2025-06-30 | $101.78M | $-84.91M | $16.87M | (m) |
| 2025-03-31 | $99.53M | $-78.58M | $20.95M | (m) |
| 2024-12-31 | $82.96M | $-73.25M | $9.71M | (m) |
| 2024-09-30 | $77.99M | $-67.00M | $10.99M | (m) |
| 2024-06-30 | $75.37M | $-62.84M | $12.53M | (m) |
| 2024-03-31 | $72.44M | $-58.42M | $14.02M | (m) |
| 2023-12-31 | $66.45M | $-54.24M | $12.20M | (m) |
| 2023-09-30 | $64.31M | $-47.62M | $16.69M | (m) |
| 2023-06-30 | $62.07M | $-41.74M | $20.33M | (m) |
| 2023-03-31 | $48.31M | $-36.03M | $12.27M | 3 month · $1.40M |
| 2022-12-31 | $46.20M | $-31.98M | $14.22M | 12 month · $1.71M |
| 2022-09-30 | $45.66M | $-25.29M | $20.37M | 3 month · $559.00K |
| 2022-06-30 | $30.91M | $-19.41M | $11.50M | 3 month · $510.00K |
| 2022-03-31 | $30.40M | $-15.84M | $14.56M | 3 month · $156.00K |
| 2021-12-31 | $1.89M | $-12.90M | $-11.01M | 12 month · $1.89M |
| 2021-09-30 | (m) | (m) | $-8.93M | 3 month · $136.00K |
| 2021-06-30 | (m) | (m) | $-4.40M | 3 month · $1.57M |
| 2021-03-31 | (m) | (m) | $-33.00K | (m) |
| 2020-12-31 | (m) | (m) | $-10.00K | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 |